Linfopenia como predictor de severidad en pacientes con infección por SARS-CoV-2

Palabras clave: COVID-19, hematología, linfocitos, pronóstico, alta del paciente

Resumen

Se ha documentado que la linfopenia es un marcador de gravedad y complicaciones en el paciente COVID-19. El objetivo fue determinar la linfopenia como parámetro de severidad en pacientes con infección por SARS-CoV-2, mediante un estudio observacional, analítico correlacional caso-control, en el cual se revisaron 140 historias clínicas. Se registraron variables sociodemográficas, clínicas de ingreso, de hospitalización, valores del hemograma y biomarcadores séricos. Las asociaciones estadísticas se estimaron mediante las pruebas Chi2 y t de student, además de ANOVA, R de Pearson y curvas de las características operativas del receptor (COR), considerando significativos valores de p<0,05. El género más frecuente fue el masculino. El grupo etario más afectado fue de 61-75 años. Las formas clínicas más sobresalientes fueron moderada y severa. Hubo diferencias entre las comorbilidades y días de hospitalización. Cuando se analizó la correlación del valor relativo de los linfocitos, no se encontraron fuerzas de asociación con las variables, solo con la forma de presentación clínica (r2: -,290) y el resultado final de la enfermedad, el valor de los linfocitos mostró mejor rendimiento para predicción del desenlace de la enfermedad. Se sugiere utilizar el valor relativo de linfocitos durante el manejo terapéutico paciente COVID-19

Citas

Velardi E, Tsai JJ, van den Brink MRM. T cell regeneration after immunological injury. Nat Rev Immunol [Internet]. 2021;21(5):277-91. Disponible en: https://doi.org/10.1038/s41577-020-00457-z DOI: 10.1038/s41577-020-00457-z PMID 33097917 PMCID PMC7583557

Bellelli V, D’Ettorre G, Celani L, Borrazzo C, Ceccarelli G, Venditti M. Clinical significance of lymphocytopenia in patients hospitalized with pneumonia caused by influenza virus. Crit Care [Internet]. 2019;23(1):330. Disponible en: https://doi.org/10.1186/s13054-019-2608-1 DOI: 10.1186/s13054-019-2608-1 PMID 31665060 PMCID PMC6819578

Shah SMA, Rasheed T, Rizwan K, Bilal M, Iqbal HMN, Rasool N, et al. Risk management strategies and therapeutic modalities to tackle COVID-19/SARS-CoV-2. J Infect Public Health [Internet]. 2021;14(3):331-46. Disponible en: https://www.sciencedirect.com/science/article/pii/S1876034120307796 DOI: 10.1016/j.jiph.2020.12.023 PMID 33618278 PMCID PMC7837232

Velavan TP, Meyer CG. The COVID-19 epidemic. Trop Med Int Heal [Internet]. 2020;25(3):278-80. Disponible en: https://onlinelibrary.wiley.com/doi/full/10.1111/tmi.13383 DOI: 10.1111/tmi.13383 PMID 32052514 PMCID PMC7169770

Stuart W, B. FM. COVID-19: Knowns, Unknowns, and Questions. mSphere [Internet]. 2020;5(2):e00203-20. Disponible en: https://doi.org/10.1128/mSphere.00203-20 DOI: 10.1128/mSphere.00203-20 PMID 32188753 PMCID PMC7082143

Gheblawi M, Wang K, Viveiros A, Nguyen Q, Zhong J-C, Turner AJ, et al. Angiotensin-Converting Enzyme 2: SARS-CoV-2 Receptor and Regulator of the Renin-Angiotensin System. Circ Res [Internet]. 2020;126(10):1456-74. Disponible en: https://doi.org/10.1161/CIRCRESAHA.120.317015 DOI: 10.1161/CIRCRESAHA.120.317015 PMID 32264791 PMCID PMC7188049

Tan L, Wang Q, Zhang D, Ding J, Huang Q, Tang Y-Q, et al. Lymphopenia predicts disease severity of COVID-19: a descriptive and predictive study. Signal Transduct Target Ther [Internet]. 2020;5(1):33. Disponible en: https://doi.org/10.1038/s41392-020-0148-4 DOI: 10.1038/s41392-020-0148-4 PMID 32296069 PMCID PMC7100419

Sathler PC. Hemostatic abnormalities in covid-19: A guided review. An Acad Bras Cienc. 2020;92(4):1-16. Disponible en: https://www.scielo.br/j/aabc/a/x7xp6VMbvrNnHpJxrXZQtkw/?lang=en DOI: 10.1590/0001-3765202020200834 PMID 32844987

Tavakolpour S, Rakhshandehroo T, Wei EX, Rashidian M. Lymphopenia during the COVID-19 infection: What it shows and what can be learned. Immunol Lett [Internet]. 2020;225:31-2. Disponible en: https://www.sciencedirect.com/science/article/pii/S0165247820303382 DOI: 10.1016/j.imlet.2020.06.013 PMID 32569607 PMCID PMC7305732

Tay MZ, Poh CM, Rénia L, MacAry PA, Ng LFP. The trinity of COVID-19: immunity, inflammation and intervention. Nat Rev Immunol [Internet]. 2020;20(6):363-74. Disponible en: https://doi.org/10.1038/s41577-020-0311-8 DOI: 10.1038/s41577-020-0311-8 PMID 32346093 PMCID PMC7187672

Fathi N, Rezaei N. Lymphopenia in COVID-19: Therapeutic opportunities. Cell Biol Int [Internet]. 2020;44(9):1792-7. Disponible en: https://doi.org/10.1002/cbin.11403 DOI: 10.1002/cbin.11403 PMID 32458561 PMCID PMC7283672

Laterre PF, François B, Collienne C, Hantson P, Jeannet R, Remy KE, et al. Association of Interleukin 7 Immunotherapy With Lymphocyte Counts Among Patients With Severe Coronavirus Disease 2019 (COVID-19). JAMA Netw Open [Internet]. 2020;3(7):e2016485-e2016485. Disponible en: https://doi.org/10.1001/jamanetworkopen.2020.16485 DOI: 10.1001/jamanetworkopen.2020.16485 PMID 32697322 PMCID PMC7376391

Rahi MS, Jindal V, Reyes S-P, Gunasekaran K, Gupta R, Jaiyesimi I. Hematologic disorders associated with COVID-19: a review. Ann Hematol [Internet]. 2021;100(2):309-20. Disponible en: https://doi.org/10.1007/s00277-020-04366-y DOI: 10.1007/s00277-020-04366-y PMID 33415422 PMCID PMC7789889

Ouyang Y, Yin J, Wang W, Shi H, Shi Y, Xu B, et al. Downregulated Gene Expression Spectrum and Immune Responses Changed During the Disease Progression in Patients With COVID-19. Clin Infect Dis [Internet]. 2020;71(16):2052-60. Disponible en: https://doi.org/10.1093/cid/ciaa462 DOI: 10.1093/cid/ciaa462 PMID 32307550 PMCID PMC7188184

Huang G, Kovalic AJ, Graber CJ. Prognostic value of leukocytosis and lymphopenia for coronavirus disease severity. Emerg Infect Dis. 2020;26(8):1839-41. Disponible en: https://wwwnc.cdc.gov/eid/article/26/8/20-1160_article DOI: 10.3201/eid2608.201160 PMID 32384045 PMCID PMC7392413

Frater JL, Zini G, D’Onofrio G, Rogers HJ. COVID-19 and the clinical hematology laboratory. Int J Lab Hematol [Internet]. 2020;42(S1):11-8. Disponible en: https://doi.org/10.1111/ijlh.13229 DOI: 10.1111/ijlh.13229 PMID 32311826 PMCID PMC7264622

Yang L, Liu S, Liu J, Zhang Z, Wan X, Huang B, et al. COVID-19: immunopathogenesis and Immunotherapeutics. Signal Transduct Target Ther [Internet]. 2020;5(1):128. Disponible en: https://doi.org/10.1038/s41392-020-00243-2 DOI: 10.1038/s41392-020-00243-2 PMID 32712629 PMCID PMC7381863

World Medical Association. World Medical Association Declaration of Helsinki: Ethical Principles for Medical Research Involving Human Subjects. JAMA [Internet]. 2013;310(20):2191-4. Disponible en: https://doi.org/10.1001/jama.2013.281053 DOI: 10.1001/jama.2013.281053 PMID 24141714

Amber L. Mueller, Maeve S.McNamara, David A. Sinclair. Why does COVID-19 disproportionately affect older people? Aging. 2020;12(10):9959-81. Disponible en: https://www.aging-us.com/article/103344/text DOI: 10.18632/aging.103344 PMID 32470948 PMCID PMC7288963

Deng Y, Liu W, Liu K, Fang Y-Y, Shang J, Zhou L, et al. Clinical characteristics of fatal and recovered cases of coronavirus disease 2019 in Wuhan, China: a retrospective study. Chin Med J (Engl) [Internet]. 2020;133(11). Disponible en: https://journals.lww.com/cmj/Fulltext/2020/06050/Clinical_characteristics_of_fatal_and_recovered.1.aspx DOI: 10.1097/cm9.0000000000000824 PMID 32209890 PMCID PMC7289311

Chen N, Zhou M, Dong X, Qu J, Gong F, Han Y, et al. Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study. Lancet [Internet]. 2020;395(10223):507-13. Disponible en: https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(20)30211-7/fulltext DOI: 10.1016/S0140-6736(20)30211-7 PMID 32007143 PMCID PMC7135076

Alharbi KS, Singh Y, Prasad Agrawal G, Altowayan WM, Almalki WH, Sharma A, et al. Synergism of CD28 Immune Molecule in Late Immunosuppressive Phase of COVID-19: Effectiveness in Vaccinated Individuals [published online ahead of print, 2022 Feb 25]. Altern Ther Health Med. 2022; PMID 35212647

Liu J, Li S, Liu J, Liang B, Wang X, Wang H, et al. Longitudinal characteristics of lymphocyte responses and cytokine profiles in the peripheral blood of SARS-CoV-2 infected patients. eBioMedicine [Internet]. 2020;55. Disponible en: https://doi.org/10.1016/j.ebiom.2020.102763 DOI: 10.1016/j.ebiom.2020.102763 PMID 32361250 PMCID PMC7165294

Clinical significance of lymphopenia in Covid-19 [Internet]. Disponible en: https://www.gmjournal.co.uk/clinical-significance-of-lymphopenia-in-older-patients-with-covid-19. 2020

Liao D, Zhou F, Luo L, Xu M, Wang H, Xia J, et al. Haematological characteristics and risk factors in the classification and prognosis evaluation of COVID-19: a retrospective cohort study. Lancet Haematol [Internet]. 2020;7(9):e671-8. Disponible en: https://doi.org/10.1016/S2352-3026(20)30217-9 DOI: 10.1016/S2352-3026(20)30217-9 PMID 32659214 PMCID PMC7351397

Lee J, Park SS, Kim TY, Lee DG, Kim DW. Lymphopenia as a biological predictor of outcomes in COVID-19 patients: A nationwide cohort study. Cancers (Basel). 2021;13(3):1-15. Disponible en: https://www.mdpi.com/2072-6694/13/3/471 DOI: 10.3390/cancers13030471 PMID 33530509 PMCID PMC7865511

Waleed A, Ahod A-A, Basma A, Alaa K, Saad A, Mohammed A, et al. Evaluation of the Levels of Peripheral CD3+, CD4+, and CD8+ T Cells and IgG and IgM Antibodies in COVID-19 Patients at Different Stages of Infection. Microbiol Spectr [Internet]. 2022;10(1):e00845-21. Disponible en: https://doi.org/10.1128/spectrum.00845-21 DOI: 10.1128/spectrum.00845-21 PMID 35196808 PMCID PMC8865559

Liu J, Li H, Luo M, Liu J, Wu L, Lin X, et al. Lymphopenia predicted illness severity and recovery in patients with COVID-19: A single-center, retrospective study. PLoS One [Internet]. 2020;15(11):e0241659. Disponible en: https://doi.org/10.1371/journal.pone.0241659 DOI: 10.1371/journal.pone.0241659 PMID 33206680 PMCID PMC7673513

Kazancioglu S, Bastug A, Ozbay BO, Kemirtlek N, Bodur H. The Role of Hematological Parameters in Patients with Coronavirus Disease 2019 and Influenza Virus Infection. Epidemiol Infect [Internet]. 2020;148. Disponible en: https://www.cambridge.org/core/journals/epidemiology-and-infection/article/role-of-haematological-parameters-in-patients-with-covid19-and-influenza-virus-infection/44070660660750E86F5FD0166F72BA3C DOI: 10.1017/S095026882000271X PMID 33148349 PMCID PMC7683813

Niu J, Sareli C, Mayer D, Visbal A, Sareli A. Lymphopenia as a Predictor for Adverse Clinical Outcomes in Hospitalized Patients with COVID-19: A Single Center Retrospective Study of 4485 Cases. J Clin Med. 2022;11(3). Disponible en: https://www.mdpi.com/2077-0383/11/3/700 DOI: 10.3390/jcm11030700 PMID 35160150 PMCID PMC8837002

Huang I, Pranata R. Lymphopenia in severe coronavirus disease-2019 (COVID-19): systematic review and meta-analysis. J Intensive Care [Internet]. 2020;8(1):36. Disponible en: https://doi.org/10.1186/s40560-020-00453-4 DOI: 10.1186/s40560-020-00453-4 PMID 32483488 PMCID PMC7245646

Illg Z, Muller G, Mueller M, Nippert J, Allen B. Analysis of absolute lymphocyte count in patients with COVID-19. Am J Emerg Med [Internet]. 2021;46:16-9. Disponible en: https://www.sciencedirect.com/science/article/pii/S0735675721001625 DOI: 10.1016/j.ajem.2021.02.054 PMID 33706251 PMCID PMC7923864

Henry B, Cheruiyot I, Vikse J, Mutua V, Kipkorir V, Benoit J, et al. Lymphopenia and neutrophilia at admission predicts severity and mortality in patients with COVID-19: a meta-analysis. Acta Biomed Atenei Parm [Internet]. 2020;91(3):e2020008. Disponible en: https://www.mattioli1885journals.com/index.php/actabiomedica/article/view/10217 DOI: 10.23750/abm.v91i3.10217 PMID 32921706 PMCID PMC7716963

Publicado
2023-01-23
Cómo citar
1.
Zavala Yamarte AY, Donoso Martel NC, Franco Yamarte AB, Contreras M, Carrero Y, Villaparedes-Moreno YF, Balza Novoa RR. Linfopenia como predictor de severidad en pacientes con infección por SARS-CoV-2. Kasmera [Internet]. 23 de enero de 2023 [citado 3 de febrero de 2023];51:e5137774. Disponible en: https://produccioncientificaluz.org/index.php/kasmera/article/view/37774
Sección
Artículos Originales

Artículos más leídos del mismo autor/a